The molecular characterization of lung cancer has led to the identification of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, which are essential for targeted molecular therapies [76]. The gene discussed is ALK; the disease is lung carcinoma.